Let’s do more
for patients, together
Freenome pursues a variety of partnerships across the healthcare ecosystem with the goal of ultimately improving care and expanding access to the patients we will serve.Partner with Freenome
Collaborating across healthcare
Our commitment to innovation and quality relationships leads to longstanding and valuable partnerships through clinical studies, targeted applications of our multiomics platform, quality improvement initiatives, and more.
Putting patients first means we champion the research and development of early stage treatments and precision therapies throughout the care continuum.
We partner with biopharma companies to leverage our platform’s capabilities and develop targeted therapies through:
- Biomarker discovery
- Treatment monitoring
- Predicting treatment response
- Minimal residual disease (MRD) detection
- Multiomics data generation in new disease areas
A selection of our work with biopharma partners
Siemens HealthineersTo identify suitable markers for early breast cancer detection
Merck KGaA, Darmstadt, GermanyTo identify signatures of non-small lung cancer
Our partnerships with organizations throughout the healthcare ecosystem—from academic institutions, to healthcare systems, providers, health plans, and more—are critical to advance early detection technology for patients and ensure that our tests are seamlessly integrated into clinical care and accessible by all.
- Clinical study sites
- Quality improvement partners
A selection of our work with research partners
Morehouse School of MedicineTo Increase Clinical Study Participation Among Black Patients
Oracle Cerner and Elligo Health ResearchTo Increase Access to Cancer Clinical Trials
Some of the most impactful work we do is in partnership with advocacy organizations. We know that these partnerships are critical to making an impact in patients’ lives, and we welcome the opportunity to work together in the pursuit of early cancer detection.Contact Partnerships team